Cardiometabolic Disorders News

Monthly lerodalcibep on top of maximum tolerated therapy reduced LDL an additional 60% over 24 weeks in patients with heterozygous familial hypercholesterolemia, with a safety profile similar vs. placebo, a speaker reported.

As allies in delivering evidence-based data, breaking news, professional resources and medical education to practicing clinicians, Healio and CMHC are proud to partner for the much-anticipated Cardiometabolic Health Congress.

Of adults with type 2 diabetes who used an incretin-based medication, the majority received an injectable GLP-1 receptor agonist in the first quarter of 2022, according to study findings.

In a new study, a diagnostic strategy utilizing tools readily available in primary care successfully identified new diagnoses of atrial fibrillation, CAD and HF among patients with type 2 diabetes or chronic obstructive pulmonary disease.

HHS announced the first 10 drugs that will be subject to Medicare price negotiations.

Adults with vitamin D deficiency may have lower COVID-19 vaccination antibody levels 9 months after the final vaccine dose compared with those with normal vitamin D levels, according to a brief report published in Endocrine.

Asymptomatic metabolic syndrome at midlife was associated with increased risk and earlier occurrence of CV events and mortality later in life, researchers reported.

In adults with HF with preserved ejection fraction and obesity, semaglutide 2.4 mg significantly improved HF-related symptoms and physical limitations and was associated with greater weight loss compared with placebo, researchers reported.

DANA POINT, Calif. — In this Healio video exclusive, Fatima Cody Stanford, MD, MPA, MPH, MBA, discusses considerations clinicians must make regarding women with obesity.

Semaglutide conferred greater reductions in HbA1c and body weight among adults with type 2 diabetes than other GLP-1 receptor agonists, according to findings from a systematic review and meta-analysis.